Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 477 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chemotherapy Effect Clear all
Completed Phase 2 Interventional

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

NCT00055718
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions
silymarin
Dietary Supplement
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
2 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
7
States / cities
Miami, Florida • Mineola, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 22, 2026, 7:16 PM EDT
Active, not recruiting Phase 3 Interventional

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

NCT05602194
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Calaspargase Pegol, Levocarnitine, Pegaspargase, Quality-of-Life Assessment
Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
15 Years to 40 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
225
States / cities
Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Not applicable Interventional

Programs to Support You During Chemotherapy (Pro-You)

NCT02148406
View directory record Official record
Conditions
Depressive Symptoms, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Stage IIA Colon Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Yoga Skills Training (YST), questionnaire administration, fatigue and depressive symptom assessment and management, psychological stress assessment, laboratory biomarker analysis, Attention Control
Behavioral · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 22, 2026, 7:16 PM EDT
Withdrawn No phase listed Observational

Cardiac 3D MRI in Pediatric Cancer Patients

NCT02130934
View directory record Official record
Conditions
Childhood Cancer
Interventions
Cardiac 3D MRI
Procedure
Lead sponsor
Majd Makhoul
Other
Eligibility
8 Years to 26 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 22, 2026, 7:16 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Dose Response Effect of Atomoxetine to the Acute Effects of Alcohol

NCT01408589
View directory record Official record
Conditions
Alcohol Craving, Mood Changes
Interventions
Atomoxetine, Strattera
Drug
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
21 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 22, 2026, 7:16 PM EDT
Recruiting Not applicable Interventional

Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer

NCT05874297
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Best Practice, Internet-Based Intervention, Questionnaire Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 7:16 PM EDT
Not listed Not applicable Interventional

Can Fasting Decrease the Side Effects of Chemotherapy?

NCT04027478
View directory record Official record
Conditions
Chemotherapy Effect, Chemotherapeutic Toxicity, Fasting
Interventions
FMD
Dietary Supplement
Lead sponsor
Sutter Health
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

NCT04121078
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Not applicable Interventional

Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients

NCT00139204
View directory record Official record
Conditions
Prostate Cancer
Interventions
C11 Methionine PET scan
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2009 · Synced Oct 22, 2026, 7:16 PM EDT
Active, not recruiting No phase listed Observational

Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors

NCT06480526
View directory record Official record
Conditions
High-risk Neuroblastoma
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 22, 2026, 7:16 PM EDT
Completed No phase listed Observational

The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients

NCT00000860
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Not applicable Interventional

Effects of Creatine Supplementation in Breast Cancer Survivors

NCT04207359
View directory record Official record
Conditions
Breast Cancer, Chemotherapy Effect, Muscle Weakness, Muscle Loss, Exercise
Interventions
Creatine
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

NCT01892189
View directory record Official record
Conditions
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions
Ketamine, TAK-063, TAK-063 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 7:16 PM EDT
Terminated Phase 2 Interventional Results available

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

NCT02732015
View directory record Official record
Conditions
Locally Advanced Sarcoma
Interventions
Dexamethasone, Doxorubicin, Fosaprepitant Dimeglumine, Ifosfamide, Laboratory Biomarker Analysis, Mesna, Ondansetron, Questionnaire Administration, Rolapitant Hydrochloride, Vincristine Sulfate
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Results available

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

NCT01664624
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chula Vista, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 2 Interventional

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

NCT00003068
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions
amifostine trihydrate, cyclophosphamide, mitoxantrone hydrochloride, thiotepa, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of Arizona
Other
Eligibility
16 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Results available

Study of MLN8237 in Participants With Advanced Solid Tumors

NCT00962091
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Results available

Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)

NCT05319860
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV), Aromatherapy Care
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 22, 2026, 7:16 PM EDT
Not listed Phase 2 Interventional

Effect of Hemp-CBD on Patients With CIPN

NCT04398446
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Breast Cancer, Ovarian Cancer, Uterine Cancer, Pancreatic Cancer
Interventions
Hemp-based CBD, Placebo oral tablet
Drug · Other
Lead sponsor
Main Line Health
Other
Eligibility
21 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

POEM (Practice Of Embracing Each Moment) STUDY

NCT03078608
View directory record Official record
Conditions
Distress, Cancer, Chemotherapy Effect
Interventions
Mindfulness meditation program (administered via mobile app), Progressive muscle relaxation (via mobile app)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 22, 2026, 7:16 PM EDT
Not listed Phase 3 Interventional Results available

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

NCT00408408
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, capecitabine, cyclophosphamide, docetaxel, doxorubicin hydrochloride (Adriamycin), gemcitabine hydrochloride
Biological · Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
1,206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
432
States / cities
Little Rock, Arkansas • Castro Valley, California • Fremont, California + 287 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 2 Interventional

Automated Telephone Monitoring for Symptom Management

NCT00799084
View directory record Official record
Conditions
Carcinoma
Interventions
Nurse, AVR
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 22, 2026, 7:16 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents

NCT00825227
View directory record Official record
Conditions
Fatigue, Chemotherapy Side Effects
Interventions
Armodafinil 150 mg/day, Placebo,
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
29
States / cities
Muscle Shoals, Alabama • Burbank, California • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 22, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Results available

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

NCT02122770
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MLN4924, Fluconazole, Itraconazole, Docetaxel, Carboplatin, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 22, 2026, 7:16 PM EDT